Foghorn Therapeutics Inc. recently raised $50 million in an equity financing round with BVF Partners, Deerfield Management, Flagship Pioneering, and a biotech mutual fund. The transaction is set to close on January 13, 2026. Their Phase 1 trial for FHD-909 targeting SMARCA4 (BRG1)-mutant cancers, specifically non-small cell lung cancer (NSCLC), is progressing as planned. They also have programs for Selective CBP and EP300 degraders that are on track for IND-ready status in 2026. With a strong balance sheet, including $208.9 million in cash and securities, Foghorn plans to continue investing in their pipeline until the first half of 2028.

Foghorn Therapeutics is focused on developing new treatments for serious diseases by correcting abnormal gene expression. The company’s strategic objectives for 2026 include advancing their pipeline and providing updates on their first-in-class programs. FHD-909, a SMARCA2 selective inhibitor, is in a Phase 1 trial for NSCLC. They are also working on Selective CBP and EP300 degraders for cancers like ER+ breast cancer and hematological malignancies. Additionally, they have a program for a Selective ARID1B degrader targeting ARID1A-mutated cancers.

Foghorn Therapeutics is collaborating with Lilly on novel oncology medicines, including a program for selective SMARCA2 inhibitors and degraders. They are also developing Selective CBP and EP300 degraders for specific cancer types. The company aims to advance their programs towards IND filings in 2026 and beyond. With a focus on genetically determined dependencies within the chromatin regulatory system, Foghorn is committed to discovering and developing innovative medicines for challenging diseases.

Read more at GlobeNewswire: Foghorn Therapeutics Highlights January Equity Financing,